Healthcare Industry News:  Parkinsonís disease 

Biopharmaceuticals Neurology

 News Release - September 21, 2012

Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinsonís Disease

NASHVILLE, Tenn. & NEW YORK--(Healthcare Sales & Marketing Network)--Vanderbilt University and Bristol-Myers Squibb Company (BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinsonís disease.

Under the collaboration, the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will identify drug candidates from its existing program, which obtained major support from The Michael J. Fox Foundation for Parkinsonís Research (MJFF). Bristol-Myers Squibb will have the right to develop and commercialize products resulting from the collaborative research program.

Under the terms of the agreement, Vanderbilt University will receive an upfront payment and multi-year research funding to continue to discover additional compounds. Vanderbilt is eligible to receive milestones and royalties based on developmental success and worldwide sales of the drugs emerging from the collaboration.

ďThe long-term commitment of and collaboration with the MJFF were critical to advancing this program to the stage where it is now perfectly positioned to work closely with Bristol-Myers Squibb for further development,Ē said P. Jeffrey Conn, Ph.D., VCNDD director and Lee E. Limbird, Chair in Pharmacology. ďPartnering with Bristol-Myers Squibb is a real win for Vanderbilt and for Parkinsonís patients.Ē

ďWe all look forward to a productive collaboration with Bristol-Myers Squibb, which brings tremendous expertise and a strong commitment to advancing the program,Ē added Craig Lindsley, Ph.D., VCNDD director of medicinal chemistry.

ďAt Bristol-Myers Squibb we are dedicated to discovering and developing medicines that address serious unmet need,Ē said Francis Cuss, MB BChir, FRCP, senior vice president for Research at Bristol-Myers Squibb. ďAs part of our strategy, we continually seek to build relationships with organizations that have innovative programs and capabilities that complement our own internal efforts. We are thrilled to have the opportunity to work with the Vanderbilt Center for Neuroscience Drug Discoveryís highly regarded scientists and laboratories to potentially find a way to help patients with Parkinsonís disease

About Parkinsonís disease

An estimated 1 million Americans have Parkinson's disease, a progressive brain disorder characterized by resting tremor, rigidity and slowness of movement. It is caused by the death of nerve cells in a specific brain region that produce the neurotransmitter dopamine.

About mGluR4 PAMs

mGluR4 receptors are highly expressed in areas of the brain directly relevant to Parkinsonís disease. mGluR4 PAMs represent an approach to correct the dysregulated signaling observed in Parkinsonís disease and pharmacologically mimic a surgical procedure that has been successful in alleviating symptoms of Parkinsonís disease.

About Vanderbilt

Vanderbilt University Medical Center is a major referral center for the Southeast and nation. Its research enterprise, which includes the Vanderbilt Center for Neuroscience Drug Discovery, is nationally known for translating scientific discoveries into patient care advances. For more information, see

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at

Source: Bristol-Myers Squibb

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.